Fig. 2
From: A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy
Therapeutic vaccination of mice bearing CT26 colorectal tumors with lentiviral vectors coding for various KRASG12D antigen designs. A Timeline of CT26 tumor inoculation and vaccination. BALB/c mice (n = 8 for Ctrl Lenti, Lenti-li-KRASG12D and Lenti-li-DT-KRASG12D groups, and n = 9 for Lenti-KRASG12D group) were engrafted s.c. on the right flank with 2 × 105 CT26 cells. Seven days later, when tumors became palpable, mice were randomized and injected i.m. with 1 × 109 TU of Ctrl Lenti, Lenti-KRASG12D, Lenti-li-KRASG12D or Lenti-li-DT-KRASG12D. B Plots of tumor size in individual mice over time. Statistical significance was determined by two-way ANOVA test by Log-rank Mantel-Cox test (*p < 0.05). C Survival curve of the animals. Statistical significance was determined by Log-rank Mantel-Cox tests (*p < 0.05). Mice were sacrificed when the tumor volume reached 1500 mm3, defined as humane endpoints. The experiment shown is representative of two independent experiments.
